Meet Us Contact Us

News

ChestLink Study: AI Accurately Identifies Normal and Abnormal Chest X-Rays
2023 March 20th
An AI tool can accurately identify normal and abnormal chest X-rays in a clinical setting, according to a study published in Radiology. The tool may greatly alleviate the heavy workload experienced by radiologists globally.  
Oxipit Partners With CARPL To Increase Global Reach Of AI Diagnostic Products
2023 March 2nd
At the European Congress of Radiology in Vienna Oxipit announced that its diagnostic AI solutions will be available on the CARPL platform. CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality - for real-time quality assurance and ChestEye - for preliminary reports. The move further builds on Oxipit strategy to increase global reach of company’s products.
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
2023 February 15th
The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency’s approval is one of Oxipit steps to increase global reach for company products.
Oxipit Closes $4.9M Funding Round To Advance AI Autonomy in Medical Imaging
2023 January 19th
AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital, Practica Capital, and Coinvest Capital. Angel investors also participated in this round. The funding will help Oxipit advance its development of autonomous AI medical imaging applications and support market expansion into new geographic regions, with particular focus on the United Kingdom.
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
2022 November 15th
AI medical imaging company Oxipit expanded its ChestEye Quality product with quality assurance support for musculoskeletal X-rays, mammography images and CT scans. The new imaging modalities will follow the same AI-powered double reading workflow as with chest X-ray images. New Quality features will be showcased at RSNA 2022 annual meeting later this month.
Kaunas City Polyclinic Picks ChestLink to Speed Up Preventive Health Checks
2022 September 28th
Kaunas city polyclinic introduced Oxipit ChestLink AI application in their preventive health check up workflow. With ChestLink, which can automatically identify normal chest X-rays, healthy patients can be instantly sent home after the examination, without the need to wait for the study report at the polyclinic. Operating with 99.9% sensitivity, ChestLink can automatically report on 26% of all X-ray studies at Kaunas city polyclinic.
Chest Experts Oxipit And contextflow Team Up For Diagnostic Quality Assurance
2022 July 13th
The new partnership aims to mitigate the risk associated with missed findings in CT medical imaging studies. The collaboration will combine Oxipit’s ChestEye Quality and contextflow’s SEARCH Lung CT products to identify missed findings in CT scans in near-real time. ECR 2022 will offer the first preview of the combined solution, and the first installation will be deployed at Leiden University Medical Center.
Study: 1 in 552 CXR Studies Feature Clinically Significant Diagnostic Errors
2022 July 12th
For the annual European Congress of Radiology meeting in Vienna, Oxipit has conducted a retrospective validation study from internal ChestEye Quality performance data at more than 10 pilot deployment institutions. The study concludes that 1 in 552 (0.18%) chest X-ray studies reported by a radiologist include clinically significant diagnostic mistakes. The vast majority - 78.46% - of the errors are missed findings of pulmonary nodules and lymphadenopathy.
ChestLink Autonomous AI Application Misses No Critical Findings In A Real-World Clinical Test
2022 May 25th
Researchers in Finland released a preprint of a study on the application performance on real-world clinical data. In the study, the application analyzed 10.000 chest X-rays of Finnish primary health care patients. ChestLink software was able to identify normal studies with 99.8% sensitivity and and specificity of 36.4% with a minimal number of false negatives that would lead to effectively no compromise on patient safety and no critical findings missed by the software.
Oxipit and AstraZeneca Join Forces to Aid Early Lung Cancer Detection
2022 April 26th
The companies conducted a joint pilot study, where Oxipit’s ChestEye Quality AI software is employed for improved pulmonary nodule detection. The software was deployed in two major primary care centers in Lithuania. With nearly 50.000 chest X-ray images analyzed over the course of 2021, ChestEye Quality helped to detect 82 additional clinically relevant nodule findings, potentially identifying additional early instances of lung cancer.

Media About Us

Society for Imaging Informatics in Medicine:

Oxipit’s Chest X-ray Search Solution Selected as One of Top Innovations by SIIM

European Congress of Radiology (ECR 2018):

Oxipit’s Peer Reviewed Poster On Multiclass Chest X-Ray Pathology Classification

Intel:

Press Release on our Kaggle win

Kaggle:

Interview on how we won the Intel & MobileODT Cervical Cancer Screening Competition

Kaggle:

Interview on how we won the Nature Conservancy Fisheries Monitoring Competition

Verslo Žinios:

Laurus pasaulio dirbtinio intelekto konkursuose pelnę lietuviai kuria bendrovę

Verslo Žinios:

Oxipit.ai apie dirbtinio intelekto kūrimą Vilniuje ir Lietuvos galimybes

Lietuvos rytas:

Šešių jaunų lietuvių kūrinys sužavėjo pasaulį